Rova-T: AbbVie's SCLC ADC failure (2018-2019)
AbbVie paid $5.8 billion in 2016 to buy Stemcentrx and its DLL3-targeted antibody-drug conjugate Rova-T, then the most hyped SCLC drug in development. Early single-arm data looked strong. When phase 3 testing began, Rova-T underperformed topotecan and AbbVie shut down the program in 2019, taking a multibillion-dollar write-down.
Rova-T never reached approval; AbbVie exited SCLC entirely.
The failure cooled investor enthusiasm for SCLC antibody-drug conjugates for years, until this new B7-H3 cohort.
Tam-Peli and Ris-Rez are answering the question Rova-T failed: can an ADC truly extend survival in small-cell lung cancer in randomized testing?
